Systematic Review and Meta-Analysis of Adjuvant I131 Lipiodol after Excision of Hepatocellular Carcinoma
Authors:
- 18 April 2014
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 21 (8) , 2700-2707
Abstract
Curative resection for hepatocellular carcinoma (HCC) has an 80 % recurrence at 5 years. Survival could be prolonged with adjuvant iodine131 lipiodol. This systematic review and meta-analysis was designed to assess the survival benefit of this treatment in patients with resected HCC compared with surgery alone. Studies were identified through a systematic search of MEDLINE, EMBASE, PubMed, and Cochrane databases in June 2013. Three case-control series and two randomized, controlled trials (RCT) were included. Two of these studies had a second publication that analyzed long-term follow-up. Two reviewers extracted data with respect to disease-free and overall survival (OS). The data from the seven studies was then subject to meta-analysis. Age, sex, liver function, tumor size, encapsulation, microvascular invasion, multifocality, and the rate of major hepatic resection were similar in the two groups. Peto odds ratio for disease-free survival was 0.47 (95 % confidence interval (CI) 0.37–0.59, I 2 = 10 %) and for OS was 0.5 (95 % CI 0.39–0.64, I 2 = 37 %), in favor of treatment. This study is limited by its comparison of two RCTs with three case-control studies. Most patients also had preserved liver function, and there was a generally low rate of microvascular invasion. Nonetheless, there is strong evidence for the use of adjuvant I131 lipiodol, to prolong disease-free and OS, up to 5 years after resection.Keywords
This publication has 22 references indexed in Scilit:
- Intra‐arterial iodine‐131‐lipiodol for unresectable hepatocellular carcinomaCancer, 2010
- Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinomaHPB, 2008
- Adjuvant Intraarterial Injection of 131I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-upJournal of Nuclear Medicine, 2008
- Prevention of intrahepatic recurrence by adjuvant 131iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosisEuropean Journal of Surgical Oncology, 2007
- The case of the misleading funnel plotBMJ, 2006
- Adjuvant Intra–Arterial Injection of Iodine–131-Labeled Lipiodol After Resection of Hepatocellular CarcinomaHepatology, 2003
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging ClassificationSeminars in Liver Disease, 1999
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Lipiodol uptake and retention by human hepatoma cellsNuclear Medicine and Biology, 1995
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973